Sanofi, Re­gen­eron etch out an­oth­er PhI­II vic­to­ry for Dupix­ent, eas­ing se­vere itch and clear­ing le­sions

Sanofi and Re­gen­eron can boast of an­oth­er in­flam­ma­to­ry dis­ease where Dupix­ent has proven ef­fec­tive.

The best-sell­ing drug, which tar­gets both IL-4 and IL-13, has de­liv­ered a clean sweep in a Phase III tri­al for pruri­go nodu­laris, a chron­ic dis­ease char­ac­ter­ized by itch so in­tense that it can af­fect pa­tients’ sleep and psy­chol­o­gy. Thick skin le­sions can cov­er most of the body.

On the pri­ma­ry end­point, 37% of pa­tients tak­ing Dupix­ent saw a clin­i­cal­ly mean­ing­ful re­duc­tion in itch com­pared to 22% of those on place­bo (p=0.0216) at week 12. All sec­ondary end­points were al­so met, in­clud­ing clear­ance of skin le­sions and im­prove­ment in qual­i­ty of life.

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER